Cleared Traditional

K113777 - QUIDEL MOLECULAR INFLUENZA A+B
(FDA 510(k) Clearance)

Mar 2012
Decision
85d
Days
Class 2
Risk

K113777 is an FDA 510(k) clearance for the QUIDEL MOLECULAR INFLUENZA A+B. This device is classified as a Influenza A And Influenza B Multiplex Nucleic Acid Assay (Class II - Special Controls, product code OZE).

Submitted by Quidel Corp. (San Diego, US). The FDA issued a Cleared decision on March 15, 2012, 85 days after receiving the submission on December 21, 2011.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3980. An Influenza A And Influenza B Multiplex Nucleic Acid Assay Is A Multiplex In Vitro Diagnostic Test For The Simultaneous Qualitative Detection And Discrimination Of Influenza A And Influenza B Nucleic Acids Isolated And Purified From Human Respiratory Specimens Obtained From Individuals Exhibiting Signs And Symptoms Of Respiratory Tract Infections Or Viral Culture. The Detection And Discrimination Of Influenza A And B Nucleic Acids From Symptomatic Patients Aid In The Diagnosis Of Human Respiratory Tract Influenza Viral Infections If Used In Conjunction With Other Clinical And Laboratory Findings..

Submission Details

510(k) Number K113777 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 21, 2011
Decision Date March 15, 2012
Days to Decision 85 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code OZE — Influenza A And Influenza B Multiplex Nucleic Acid Assay
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3980
Definition An Influenza A And Influenza B Multiplex Nucleic Acid Assay Is A Multiplex In Vitro Diagnostic Test For The Simultaneous Qualitative Detection And Discrimination Of Influenza A And Influenza B Nucleic Acids Isolated And Purified From Human Respiratory Specimens Obtained From Individuals Exhibiting Signs And Symptoms Of Respiratory Tract Infections Or Viral Culture. The Detection And Discrimination Of Influenza A And B Nucleic Acids From Symptomatic Patients Aid In The Diagnosis Of Human Respiratory Tract Influenza Viral Infections If Used In Conjunction With Other Clinical And Laboratory Findings.

Similar Devices — OZE Influenza A And Influenza B Multiplex Nucleic Acid Assay

All 19
CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2); Influenza A SubTyping Kit (VER 4); Influenza B Genotyping Kit (VER 1.1 and 2); and Influenza A/H5 Subtyping Kit (VER 4)
K243274 · Centers For Disease Control and Prevention · Jul 2025
CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2); Influenza A Subtyping Kit (VER 4); Influenza B Lineage Genotyping Kit (VER 1.1 and 2); and Influenza A/H5 Subtyping Kit (VER 4)
K243931 · Centers For Disease Control and Prevention · Mar 2025
CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit (Ver4)
K241110 · Centers For Disease Control and Prevention · May 2024
Lyra Influenza A+B Assay
K230236 · Quidel Corporation · Mar 2023
ID Now Instrument, ID Now Influenza A & B 2, ID NOW Strep A 2
K220801 · Abbott Diagnostics Scarborough, Inc. · Jun 2022
CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit, CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza A/H5 Subtyping Kit
K200370 · Centers For Disease Control and Prevention · Mar 2020